CNTA | tickerfilter.com

Fundamental analysis

28%

Profitability 0%

Dept financing 34%

Liquidity 50%

Performance 50%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

4.26%

1 Month

-25.57%

3 Months

-24.81%

6 Months

-24.90%

1 Year

5.47%

2 Year

209.47%

Key data

Stock price

$11.76

P/E Ratio

0.00

DAY RANGE

$9.60 - $12.34

EPS

-$2.06

52 WEEK RANGE

$7.75 - $19.09

52 WEEK CHANGE

-$0.93

MARKET CAP

1.917 B

YIELD

N/A

SHARES OUTSTANDING

113.178 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-12-2025

BETA

0.96

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,466,160

AVERAGE 30 VOLUME

$1,235,021

Company detail

CEO: Saurabh Saha
Region: US
Website: centessa.com
Employees: 200
IPO year: 2021

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Centessa Pharmaceuticals plc discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor. SerpinPC, an activated protein C inhibitor, is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage.

CNTA - Centessa Pharmaceuticals plc